An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
Puumala hantavirus (PUUV) causes a hemorrhagic fever with renal syndrome (HFRS), also called nephropathia epidemica (NE), which is mainly endemic in Europe and Russia. The clinical features include a low platelet count, altered coagulation, endothelial activation, and acute kidney injury (AKI). Multiple connections between coagulation pathways and inflammatory mediators, as well as complement and kallikrein-kinin systems, have been reported. The bleeding symptoms are usually mild. PUUV-infected patients also have an increased risk for disseminated intravascular coagulation (DIC) and thrombosis.
Vasculopathy in HFRS. Hantaviruses infect endothelial cells (EC) lining the vasculature. The infected…
Figure 1
Vasculopathy in HFRS. Hantaviruses infect endothelial cells (EC) lining the vasculature. The infected ECs express viral Gn/Gc glycoproteins and upregulate ICAM-1 adhesion molecules, to which circulating platelets and neutrophils adhere. The interactions activate platelets and neutrophils (through neutrophil extracellular traps, NETs), which promote coagulation through thrombus and fibrin clot formation. At the same time, the infected ECs induce the local production of bradykinin that is released into the bloodstream, which, together with complement membrane attack complex, compromises the EC barrier function, resulting in increased blood flow into tissues. Another factor produced by infected ECs, tissue plasminogen activator (tPA) solubilizes blood clots and thereby contributes to EC permeability. The activity of tPA is inhibited by plasminogen activator inhibitor (PAI)-1 that is upregulated in the more severe HFRS cases (caused by DOBV hantavirus). This image was created with BioRender.com.
Vaheri A., Henttonen H., Voutilainen L., Mustonen J., Sironen T., Vapalahti O. Hantavirus infections in Europe and their impact on public health. Rev. Med. Virol. 2013;23:35–49. doi: 10.1002/rmv.1722.
-
DOI
-
PubMed
Vapalahti O., Mustonen J., Lundkvist Å., Henttonen H., Plyusnin A., Vaheri A. Hantavirus infections in Europe. Lancet Infect. Dis. 2003;3:653–661. doi: 10.1016/S1473-3099(03)00774-6.
-
DOI
-
PubMed
Jonsson C.B., Figueiredo L.T., Vapalahti O. A global perspective on hantavirus ecology, epidemiology, and disease. Clin. Microbiol. Rev. 2010;23:412–441. doi: 10.1128/CMR.00062-09.
-
DOI
-
PMC
-
PubMed
Makary P., Kanerva M., Ollgren J., Virtanen M.J., Vapalahti O., Lyytikäinen O. Disease burden of Puumala virus infections, 1995–2008. Epidemiol. Infect. 2010;138:1484–1492. doi: 10.1017/S0950268810000087.
-
DOI
-
PubMed
Vaheri A., Strandin T., Hepojoki J., Sironen T., Henttonen H., Mäkelä S., Mustonen J. Uncovering the mysteries of hantavirus infections. Nat. Rev. Microbiol. 2013;11:539–550. doi: 10.1038/nrmicro3066.
-
DOI
-
PubMed